As filed with the Securities and Exchange Commission on March 25, 2019.
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER THE SECURITIES ACT OF 1933
REGISTRATION STATEMENT
UNDER THE SECURITIES ACT OF 1933
MEDIWOUND LTD.
(Exact Name of Registrant as Specified in its charter)
(Exact Name of Registrant as Specified in its charter)
ISRAEL (State or other jurisdiction of Incorporation or Organization) | Not Applicable (I.R.S. Employer Identification Number) |
42 Hayarkon Street
Yavne, 8122745 Israel
(Address of Principal Executive Offices) (Zip Code)
MediWound Ltd. 2014 Equity Incentive Plan
(Full title of the plan)
Puglisi & Associates
850 Library Avenue, Suite 204
Newark, Delaware 19711
(Name and address of agent for service)
+1 (302) 738-6680
(Telephone number, including area code, of agent for service)
Copy to: Joshua G. Kiernan Latham & Watkins LLP 99 Bishopsgate London EC2M 3XF United Kingdom +44 20 7710 1000 | David S. Glatt, Adv. Haim Gueta, Adv. Jonathan M. Nathan, Adv. Meitar Liquornik Geva Leshem Tal 16 Abba Hillel Silver Rd. Ramat Gan 5250608, Israel Tel: +972 (3) 610-3100 Fax: +972 (3) 610-3111 |
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer ☐ Non-accelerated filer ☐ Emerging Growth Company ☒ | Accelerated filer ☒ Smaller reporting company ☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨☒
CALCULATION OF REGISTRATION FEE
Title of Each Class of Securities to be Registered | Amount to be Registered(1) | Proposed Maximum Offering Price per Unit | Proposed Maximum Aggregate Offering Price | Amount of Registration Fee | ||||||||||||
543,577(2 | ) | $ | $5.14 | (3) | $ | 2,793,985.78 | (3) | $ | 338.63 |
(1) | In accordance with Rule 416 under the Securities Act of 1933, as amended, this registration statement shall be deemed to cover any additional securities that may from time to time be offered or issued to prevent dilution resulting from stock splits, stock dividends or similar transactions. |
(2) | Consists of an additional 543,577 shares issuable under the MediWound Ltd. 2014 Equity Incentive Plan, as amended (the “2014 Plan”). |
(3) | Estimated solely for the purpose of calculating the registration fee pursuant to Rules 457(c) and 457(h) of the Securities Act of 1933, as amended, and based upon the average of the high and low prices of the Registrant’s Ordinary Shares as reported on The Nasdaq Global Market on March 19, 2019. |
EXPLANATORY NOTE
This Registration Statement on Form S-8 is being filed for the purpose of registering an additional 543,577 shares of the Registrant’s Ordinary Shares to be issued under the 2014 Plan, for which Registration Statements on Form S-8 of the Registrant relating to such employee benefit plan are effective.
STATEMENT OF INCORPORATION BY REFERENCE
This Registration Statement on Form S-8 hereby incorporates by reference the contents of the Registration Statements on Form S-8 (File Nos. 333-223767, 333-210375 and 333-195517).
Item 8. Exhibits.
INDEX TO EXHIBITS
Exhibit Number | Description | |
(1) | Filed as Exhibit 3.2 on March 14, 2014 pursuant to a registration statement on Form F-1 (File No. 333-193856) and incorporated by reference herein. |
(2) | Filed as Exhibit 1.2 on February 12, 2015 pursuant to the Registrant’s Annual Report on Form 20-F for the year ended December 31, 2014 (File No. 001-36349) and incorporated by reference herein. |
(3) | Filed as Exhibit 1.3 on March 25, 2019 pursuant to the Registrant’s Annual Report on Form 20-F for the year ended December 31, 2018 (File No 001-36349 ) and incorporated by reference herein. |
(4) | Filed as Exhibit 3.3 on March 3, 2014 pursuant to a registration statement on Form F-1 (File No. 333-193856) and incorporated by reference herein. |
(5) | Filed as Exhibit 10.8 on March 3, 2014 pursuant to a registration statement on Form F-1 (File No. 333-193856) and incorporated by reference herein. |
(6) | Filed as Exhibit 4.10 on March 25, 2019 pursuant to the Registrant’s Annual Report on Form 20-F for the year ended December 31, 2018 (File No 001-36349 ) and incorporated by reference herein. |
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Yavne, Israel, on March 25, 2019.
MEDIWOUND LTD. | |||
By: | /s/ Sharon Malka | ||
Name: Sharon Malka | |||
Title: Chief Financial Officer | |||
Each person whose signature appears below hereby constitutes and appoints Gal Cohen or Sharon Malka, and each of them, his true and lawful attorneys-in-fact and agents, with full power to act separately and full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to file the same, with all exhibits thereto, and all other documents in connection therewith, with the Securities and Exchange Commission, granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or either of them or his or her or their substitute or substitutes may lawfully do or cause to be done by virtue hereof.Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities indicated and on the date indicated.
Signature | Title | Date | ||
/s/ Gal Cohen | President and Chief Executive Officer | March 25, 2019 | ||
Gal Cohen | (Principal Executive Officer) | |||
/s/ Sharon Malka | Chief Financial and Operation Officer | March 25, 2019 | ||
Sharon Malka | (Principal Financial and Accounting Officer) | |||
/s/ Stephen T. Wills | Active Chairman of the Board and Director | March 25, 2019 | ||
Stephen T. Wills | ||||
/s/ Ofer Gonen | Director | March 25, 2019 | ||
Ofer Gonen | ||||
/s/ Vickie R. Driver | Director | March 25, 2019 | ||
Vickie R. Driver | ||||
/s/ Nissim Mashiach | Director | March 25, 2019 | ||
Nissim Mashiach | ||||
/s/ Sharon Kochan | Director | March 25, 2019 | ||
Sharon Kochan | ||||
/s/ Assaf Segal | Director | March 25, 2019 | ||
Assaf Segal | ||||
PUGLISI & ASSOCIATES | Authorized Representative in the United States | March 25, 2019 |
By: /s/ Donald J. Puglisi
Name: Donald J. Puglisi
Title: Managing Director